Comparative Pharmacology
Head-to-head clinical analysis: CROLOM versus CROMOLYN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CROLOM versus CROMOLYN SODIUM.
CROLOM vs CROMOLYN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CROLOM is a selective estrogen receptor modulator (SERM) that binds to estrogen receptors, blocking estrogen-mediated signaling in target tissues, thereby inhibiting growth of hormone-sensitive breast cancer cells.
Stabilizes mast cell membranes, inhibiting release of histamine and other mediators of inflammation.
2 capsules (each containing 40 mg cromolyn sodium) orally 4 times daily, 30 minutes before meals and at bedtime.
For bronchial asthma: 20 mg (2 capsules) orally 4 times daily, administered 1 hour before meals and at bedtime. For allergic rhinitis: 1 spray (5.2 mg) in each nostril 3-6 times daily. For mastocytosis: 200 mg orally 4 times daily.
None Documented
None Documented
Terminal half-life 8-12 hours in normal renal function; extended to 20-30 hours in severe impairment
Terminal elimination half-life is approximately 1-1.5 hours for the absorbed fraction; the short half-life necessitates frequent dosing (e.g., 4 times daily) for sustained clinical effect.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Primarily excreted unchanged in bile and feces (approximately 98% after oral administration); renal excretion is minimal (<1% unchanged in urine). After inhalation, a small amount is absorbed systemically and similarly excreted via bile/feces.
Category C
Category A/B
Mast Cell Stabilizer
Mast Cell Stabilizer